Currently, no cure exists for Alzheimer’s disease, the devastating neurological disease affecting more than 5 million Americans.
But scientists are now reporting new progress on a set of compounds, initially developed for cancer treatment, that shows promise as a potential oral therapy for Alzheimer’s. Their study appears in ACS’ Journal of Medicinal Chemistry.
Carlo Ballatore, Kurt R. Brunden and colleagues explain that in a healthy brain, the protein known as tau binds to and stabilizes microtubules, which are cellular components made of protein inside cells. Microtubules are critical for performing many processes in the cell, such as growth and division. In the brain, they are particularly important for transporting molecules or other “cargo,” such as nutrients. But in people with Alzheimer’s disease, tau doesn’t bind well to microtubules and clumps up in the brain. That leaves microtubules in disarray. Scientists believe that this process leads to the mental problems associated with the disease, including memory loss, dementia and ultimately nerve cell death. The researchers have previously shown that when agents that can stabilize microtubules are given to mice with Alzheimer-like traits, their cognition has improved, and nerve cell loss is reduced. But the experimental compounds so far have not been good drug candidates mainly because they must be injected, which can be painful. The Ballatore and Brunden teams wanted to test a series of compounds, already identified as potential anti-fungal and anti-cancer agents, that patients might one day be able to take orally.
They gave the compounds to mice by mouth and found that the drugs reached the brain, took on the role of tau and stabilized microtubules in the animals’ brains. This led the scientists to conclude that the molecules from these classes could be good oral therapy candidates for treating Alzheimer’s and related disorders.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Citizen journal: Alzheimer’s robs victims, their loved oneson December 3, 2020 at 5:21 am
If you are past middle age, you may have the opportunity to reconnect with a dear friend from decades ago. If the friendship was deep, you and your friend pick up right where you left off back in the ...
- Neuroglee Therapeutics to Attack Alzheimer's Disease Through Personalized AI-Powered Digital Therapeuticson December 3, 2020 at 3:50 am
Neuroglee Therapeutics, which builds personalized evidence-based prescription digital therapeutics for neurodegenerative diseases, has announced its company launch with $2.3 million in pre-seed ...
- New blood test to help diagnose Alzheimer's comes with a caveaton December 2, 2020 at 10:41 pm
The new test is not approved by the FDA and is not supported by the Alzheimer's Association. But advocates are encouraged by the research.
- Company Developes New Way To Diagnose Alzheimer'son December 2, 2020 at 6:41 pm
Matthew Meyer, senior proteomics scientist, and Stephanie Knapik, a research associate, work with the Hamilton MICROLAB STAR Liquid Handler at C2N Diagnostics in the Center for Emerging Technologies ...
- Coming Up: New research into Alzheimer’s disease and dementiaon December 2, 2020 at 2:07 pm
What’s new with Alzheimer’s disease research? Two dementia investigators talk about racial disparities, sleep and a blood test that may tell you if you’re at risk.
- Walk to End Alzheimer’s raises more than $108,000 in Sarasota and Manatee countieson December 2, 2020 at 1:33 pm
Hundreds of Sarasota and Manatee County residents helped lead the way by participating in the annual Walk to End Alzheimer’s.
- First blood test to help diagnose Alzheimer’s goes on saleon December 2, 2020 at 4:33 am
AP A company has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also ...
- Study: Air pollution exposure may be linked to Alzheimer's disease riskon December 2, 2020 at 12:05 am
Older adults exposed to air pollution might have a heightened risk of abnormal "plaque" accumulation in the brain, a new study suggests.
- New tests identify early changes in Alzheimer’s disease before symptoms appearon December 1, 2020 at 8:11 pm
Researchers have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop. The scientists developed new tools to detect ...
- First Alzheimer's blood test now on the market, without FDA approvalon December 1, 2020 at 1:00 pm
More than 5 million people in the United States and millions more around the world have Alzheimer's, the most common form of dementia.
via Bing News